Single Ascending Doses of HER-096 in Healthy Subjects
Status:
Completed
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by
comparing the effects of active study treatment HER-096 to placebo (0.9% physiological
saline). In addition, the pharmacokinetic profile of HER-096 in humans will be investigated.
The investigational medicinal products will be administered as a single dose by subcutaneous
injection.